SurModics Announces Gerald B. Fischer’s Retirement from Board of Directors
February 05 2015 - 4:15PM
Business Wire
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification and in vitro diagnostic technologies to the healthcare
industries, today announced that Gerald B. (Jerry) Fischer has
retired from the board of directors, effective immediately. Fischer
is stepping down for personal health reasons. Following Fischer’s
retirement, the SurModics board now consists of eight members,
seven of whom are independent. At present, the board does not
intend to fill the vacancy created as a result of Fischer’s
retirement as it is the Company’s intention to reduce the size of
the Board over time.
Fischer, who joined the board in 2002, was the former president
and chief executive officer of the University of Minnesota
Foundation. During his time with SurModics, he served on the audit
and corporate governance and nominating committees and helped guide
SurModics through a number of significant milestones in the
Company’s evolution.
“On behalf of our Board and the SurModics management team, we
thank Jerry for his outstanding service and longstanding commitment
to the Company,” stated Scott Ward, Chairman of the Board. “Jerry
has been an extraordinary Board member, and we greatly appreciate
the leadership, insight and financial expertise he has provided
over the past 12 years. We are grateful for his thoughtful
guidance, and we wish him all the best in the future.”
Gary Maharaj, SurModics’ chief executive officer, further added,
“I have enjoyed and benefited from Jerry's service to the Board. I
will greatly miss his collaborative leadership style, deeps
insights and sage counsel.”
About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and
enhance the well-being of patients by providing the world’s
foremost, innovative surface modification technologies and in vitro
diagnostic chemical components. The Company partners with the
world’s leading and emerging medical device, diagnostic and life
science companies to develop and commercialize innovative products
designed to improve patient diagnosis and treatment. Core offerings
include surface modification coating technologies that impart
lubricity, prohealing, and biocompatibility capabilities; and
components for in vitro diagnostic test kits and microarrays.
SurModics is headquartered in Eden Prairie, Minnesota. For more
information about the Company, visit www.surmodics.com. The content
of SurModics’ website is not part of this press release or part of
any filings that the Company makes with the SEC.
SurModics, Inc.Andy LaFrence, 952-500-7000Vice President of
Finance and Chief Financial Officerir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024